Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 3/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | TDO2 | P48775 | 1/20 | 0.34 |
| ▸ | FABP7 | O15540 | 1/20 | 0.34 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | DRD1 | P21728 | 1/20 | 0.33 |
| ▸ | DRD4 | P21917 | 1/20 | 0.33 |
| ▸ | DRD5 | P21918 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29393453 | 0.81 | CA1 (0.53) | HTR2ACA1CA2TSHRKMT2A | |
| SCHEMBL12719 | 0.81 | CA1 (0.53) | HTR2ACA1CA2TSHRKMT2A | |
| Methylene Chloride SCHEMBL28181606 | 0.76 | CA1 (0.49) | HTR2ACA1CA2TSHRKMT2A | |
| SCHEMBL9328044 | 0.75 | PPARG (0.42) | HTR2ACA1CA2PPARGPPARA | |
| SCHEMBL5353138 | 0.75 | HTR2A (0.64) | HTR2ACA1CA2KMT2ATDO2 | |
| SCHEMBL28923189 | 0.75 | HTR2A (0.48) | HTR2ACA1CA2TSHRKMT2A | |
| SCHEMBL431542 | 0.74 | HTR2A (0.44) | HTR2ACA1CA2PPARGPPARA | |
| SCHEMBL27707914 | 0.74 | HTR2C (0.41) | HTR2AHSD17B10 | |
| SCHEMBL5933468 | 0.73 | KMT2A (0.43) | HTR2ACA1CA2PPARGPPARA | |
| SCHEMBL5933473 | 0.73 | PPARG (0.46) | HTR2ACA1CA2PPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100233415-A1 | OPTICAL RECORDING MEDIUM AND AZO METAL CHELATE COMPOUND | MITSUI CHEMICALS, INC. (JP) | 2010-09-16 | — | — | US | disclosed |
| US-20090306376-A1 | OPTICAL RECORDING MEDIUM AND COMPOUND USED FOR THE SAME | MITSUI CHEMICALS, INC. (JP) | 2009-12-10 | — | — | US | disclosed |
| EP-1997856-A1 | OPTICAL RECORDING MEDIUM AND AZO METAL CHELATE COMPOUND | Mitsui Chemicals, Inc. (JP) | 2008-12-03 | — | — | EP | disclosed |
| EP-1930339-A2 | Imide compound | MITSUI CHEMICALS, INC. (JP) | 2008-06-11 | — | — | EP | disclosed |
| US-20070054084-A1 | Optical recording medium and compound used for the same | MITSUI CHEMICALS, INC. (JP) | 2007-03-08 | — | — | US | disclosed |
| US-7094516-B2 | Benzobisazole compound and optical recording medium containing the compound | MITSUI CHEMICALS, INC. (JP) | 2006-08-22 | — | — | US | disclosed |
| EP-1672626-A1 | OPTICAL RECORDING MEDIUM AND COMPOUND USED IN THE OPTICAL RECORDING MEDIUM | Mitsui Chemicals, Inc. (JP) | 2006-06-21 | — | — | EP | disclosed |
| EP-1247655-B1 | OPTICAL RECORDING MEDIUM AND NOVEL AZAPORPHYRIN COMPOUNDS | MITSUI CHEMICALS INC (JP) | 2006-05-31 | — | — | EP | disclosed |
| US-20060088786-A1 | Rewritable optical information recording medium, recording and reproducing methods, as well as recording and reproducing apparatus | MITSUI CHEMICALS, INC. (JP) | 2006-04-27 | — | — | US | disclosed |
| EP-1262966-B1 | Optical recording medium and novel azaporphyrin compound | MITSUI CHEMICALS INC (JP) | 2006-04-12 | — | — | EP | disclosed |
| EP-0637318-B1 | PEPTIDE DERIVATIVES CORRESPONDING TO THE CARBOXY TERMINAL SEQUENCE OF HIRUDIN | CIBA GEIGY AG (CH) | 1998-04-01 | — | — | EP | disclosed |
| US-5686564-A | Peptide derivatives corresponding to the carboxy terminal sequence of hirudin | NOVARTIS CORPORATION (US) | 1997-11-11 | — | — | US | disclosed |
| EP-0705279-A1 | TOPOLOGICALLY SEGREGATED, ENCODED SOLID PHASE LIBRARIES | SELECTIDE CORPORATION (US) | 1996-04-10 | — | — | EP | disclosed |
| EP-0693081-A1 | CYCLIC COMPOUNDS AND COMPOSITIONS WHICH INHIBIT BONE RESORPTION | Novartis AG (CH) | 1996-01-24 | — | — | EP | disclosed |
| EP-0637318-A1 | PEPTIDE DERIVATIVES CORRESPONDING TO THE CARBOXY TERMINAL SEQUENCE OF HIRUDIN | Novartis AG (CH) | 1995-02-08 | — | — | EP | disclosed |
| WO-1994024153-A1 | CYCLIC COMPOUNDS AND COMPOSITIONS WHICH INHIBIT BONE RESORPTION | CIBA-GEIGY AG (CH) | 1994-10-27 | — | — | WO | disclosed |
| US-5354843-A | Flanking peptides of calcitonin and processes for their manufacture | CIBA-GEIGY CORPORATION (US) | 1994-10-11 | — | — | US | disclosed |
| EP-0571087-A1 | Cleavable phosphoramidites | ROHM AND HAAS COMPANY (US) | 1993-11-24 | — | — | EP | disclosed |
| WO-1993022344-A1 | PEPTIDE DERIVATIVES CORRESPONDING TO THE CARBOXY TERMINAL SEQUENCE OF HIRUDIN | CIBA-GEIGY AG (CH) | 1993-11-11 | — | — | WO | disclosed |
| EP-0356395-A2 | Flanking peptides and process for their preparation | CIBA-GEIGY AG (CH) | 1990-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306376-A1 | OPTICAL RECORDING MEDIUM AND COMPOUND USED FOR THE SAME | CACNA1B, KCNN4, KCNN2 | HTR2A 412/4885CA1 174/4885CA2 182/4885 |
| US-20060088786-A1 | Rewritable optical information recording medium, recording and reproducing methods, as well as recording and reproducing apparatus | ALPG, TRPC6, GNRHR | HTR2A 277/4885CA1 74/4885CA2 660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.